Dr. Avigan on CAR T-Cell Therapy in Lymphoproliferative Disease

Video

David E. Avigan, MD, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.

David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.

CAR T-cell therapy, according to Avigan, has been transformative in lymphoproliferative diseases such as acute lymphocytic leukemia and non-Hodgkin lymphoma. The approach is now being investigated in multiple myeloma with a focus on BCMA as a target, which is predominantly expressed in plasma cells.

The results with CAR T-cell therapy vary and have included some high response rates, including in patients with advanced disease. The next step is to examine the durability of these responses. One study with longer follow-up suggested a median time of response of 12 months, with a little duration of response in patients with advanced disease.

Avigan believes researchers need to make progress in understanding why patients are relapsing and what can be done to preserve response. Efforts to do so include investigating mechanisms of resistance and sequencing of CAR T-cell therapy, concludes Avigan.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute